Monogram Orthopaedics, Inc. Stock

Equities

MGRM

US6097861081

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
1.87 USD -4.10% Intraday chart for Monogram Orthopaedics, Inc. -20.76% -45.64%
Sales 2024 * 1.11M Sales 2025 * 5.66M Capitalization 59.16M
Net income 2024 * -13M Net income 2025 * -16M EV / Sales 2024 * 53.3 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 10.5 x
P/E ratio 2024 *
-4.35 x
P/E ratio 2025 *
-3.67 x
Employees 28
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.84%
More Fundamentals * Assessed data
Dynamic Chart
Top Premarket Decliners MT
Monogram Orthopaedics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Monogram Orthopaedics, Inc. Elects Colleen Gray to Its Board CI
Monogram Orthopaedics, Inc. Delivers First Surgical Robot CI
Certain Common Stock of Monogram Orthopaedics, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2023. CI
Top Premarket Decliners MT
Monogram Orthopaedics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Monogram Orthopaedics Files Shelf for Up to 6.5 Million Common Shares MT
Monogram Orthopaedics Inc. Announces Completion of the Development Phase and the Start of the Verification Phase for its Next-Generation Autonomous Surgical Robotic System CI
Monogram Orthopaedics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Monogram Orthopaedics, Inc. announced that it expects to receive $19.999997 million in funding from B. Riley Principal Capital II, LLC CI
Monogram Orthopaedics Receives Conditional Purchase Order to Begin Pilot Program With Global Distributor MT
Monogram Orthopaedics Inc. Secures First Conditional Purchase Order to Initiate Pilot Program with Global Distributor CI
Monogram Orthopaedics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Monogram Orthopaedics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program CI
More news
1 day-4.10%
1 week-20.76%
Current month-9.44%
1 month-18.70%
3 months-42.99%
6 months-35.52%
Current year-45.64%
More quotes
1 week
1.82
Extreme 1.82
2.65
1 month
1.82
Extreme 1.82
4.90
Current year
1.53
Extreme 1.53
4.90
1 year
1.53
Extreme 1.53
48.99
3 years
1.53
Extreme 1.53
48.99
5 years
1.53
Extreme 1.53
48.99
10 years
1.53
Extreme 1.53
48.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 18-03-31
Founder 54 14-12-31
Director of Finance/CFO 55 22-12-31
Members of the board TitleAgeSince
Director/Board Member 68 22-10-31
Director/Board Member 60 16-03-31
Director/Board Member 68 Nov. 29
More insiders
Date Price Change Volume
24-05-02 1.87 -4.10% 70,531
24-05-01 1.95 -5.57% 224,853
24-04-30 2.065 -8.22% 112,227
24-04-29 2.25 -7.52% 212,629
24-04-26 2.433 +3.09% 40,285

Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT

More quotes
Monogram Orthopaedics Inc. (Monogram) is engaged in developing a product solution architecture that enables patient-optimized orthopedic implants by linking three-dimensional (3D) printing and robotics with advanced pre-operative imaging. Its primary business is to market orthopedic implants insertable with its orthopedic robot. The Company has a robot prototype that can autonomously execute optimized paths for precision insertion of implants in simulated cadaveric surgeries. The Monogram robotic system and related hardware (end-effector) are multi-use capital equipment. The Monogram technology platform consists of a workflow to prepare a patient-specific surgical plan from a computed tomography (CT) scan. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
More about the company